2025-04-10T17:39:01.000Z

---

In an insightful analysis, we recently unveiled a list of ten stocks that saw significant insider selling in April, coinciding with President Donald Trumps announcement of new tariffs. This article will delve deeper into the situation surrounding Zai Lab Limited (NASDAQ:ZLAB) and how it stacks up against other stocks experiencing similar insider selling during this tumultuous period.

Last week, President Trump signed an executive order that implemented a minimum 10% tariff on all imports entering the United States, sparking a wave of reactions across various sectors. Among the more drastic measures, a staggering 104% tariff was placed on imports from China. In a swift response, Beijing announced plans to raise tariffs on U.S. imports from 34% to 84%, escalating an already tense trade standoff.

In the midst of these developments, Treasury Secretary Scott Bessent conveyed an optimistic outlook to bankers, stating that the economy remains in pretty good shape. However, contrasting this viewpoint, JPMorgan CEO Jamie Dimon shared concerns regarding a potential recession lurking on the horizon, as reported by the Wall Street Journal.

Meanwhile, the Bank of England issued a warning that the announcements regarding U.S. tariffs could lead to a material increase in risks to global growth as well as heightened inflation levels, according to a report from The Guardian.

Amidst this economic turbulence, President Trump made an unexpected announcement on Wednesday, declaring a complete three-month pause on all reciprocal tariffs, although this did not include tariffs on China. This abrupt shift may have influenced the behavior of company insiders, leading to a mix of buying and selling activities in April.

During this period, while some insiders opted to capitalize on the market dip by purchasing shares, others chose to liquidate parts of their holdings. Analyzing insider trading activity can provide valuable insights; for instance, when corporate executives purchase stocks, it often indicates confidence in the companys future performance. Conversely, insider selling does not always signal trouble for the firm, as such actions can stem from personal financial decisions or a strategic move towards diversification. Therefore, it's crucial to assess insider trading alongside a company's financial health and the broader market landscape.

Our Methodology

Our focus today is on stocks that have been heavily sold off by insiders throughout April. Utilizing Insider Monkeys insider trading screener, we identified companies where at least five insiders sold shares between April 2 and April 8. From this compilation, we ranked the top ten stocks by the total value of insider sales.

Our research findings suggest that we can achieve superior market performance by mirroring the top investment choices made by leading hedge funds. By concentrating on insider trading reports and stock selections highlighted in hedge fund investor newsletters and conferences, our quarterly newsletter strategy identifies 14 small-cap and large-cap stocks each quarter. Impressively, this strategy has yielded a remarkable return of 373.4% since May 2014, significantly outperforming its benchmark by 218 percentage points.

Zai Lab Limited (ZLAB): A Key Player Among Stocks Insiders Sold in April

Zai Lab Limited (NASDAQ:ZLAB) is a prominent biopharmaceutical company committed to the development and commercialization of innovative treatments across multiple therapeutic areas, including oncology, immunology, neuroscience, and infectious diseases. The company markets several notable products, including Zejula for ovarian cancer, VYVGART for myasthenia gravis, and NUZYRA for bacterial infections, among others. Headquartered in Shanghai, China, Zai Lab collaborates with various global pharmaceutical companies to enhance its pipeline of groundbreaking therapies. Notably, it has been recognized as one of the top ten best-performing growth stocks projected for 2025.